Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and ...

A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...

Hormone therapy has endured a rather bumpy history after the Women’s Health Initiative published clinical trial data in 2002 ...

MENOPAUSAL THERAPY IN FOCUS — The FDA will hold a panel discussion Thursday on hormone therapy for menopausal women, a pet ...

Board-certified rheumatologist Dr. Mahsa Tehrani breaks down the benefits of hormone replacement therapy on treating ...

Experts worry the warning on vaginal estrogen menopause treatments is doing more harm than good and is not supported by science.

The US could scrap warnings on hormone replacement therapy (HRT) in a major shake-up of the treatment for menopause. The Food ...

The FDA has accepted for review the resubmitted NDA for ND0612 for the treatment of motor fluctuations in patients with Parkinson disease.

The FDA has accepted for Priority Review the BLA for RGX-121 for the treatment of mucopolysaccharidosis II, also known as Hunter syndrome.

HHS Secretary Robert F. Kennedy Jr. asked the FDA "to review the latest data on mifepristone ," but experts say concerns about the abortion pill's safety are misguided.

FDA to review nutrients in baby formula: 3 things for parents to know The agency says this is the first comprehensive review since 1988.

The FDA granted Breakthrough Therapy Designation for the treatment of patients with recurrent LGSOC after one or more prior lines of therapy, including platinum-based chemotherapy, in May 2021.